Diabetes mellitus

ISSN 2072-0351 (Print)
ISSN 2072-0378 (Online)

eng | рус

Preview

Diabetes mellitus

Advanced search

Archives

Combination of osteogenesis imperfecta and type 1 diabetes mellitus

D. A. Marmalyuk, G. E. Runova, S. E. Moshenina, M. P. Shapka, V. V. Fadeyev

https://doi.org/10.14341/DM12721

Full Text:

PDF (Rus) HTML (Rus) XML (Rus)

Generate QR code

Abstract

Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder accompanied by increased bone fragility. Five types of OI are distinguished on the basis of phenotypic manifestations. OI type 1 is characterized by a reduced amount of normal type 1 collagen and is the mildest form. In addition to the fractures, course of disease can be accompanied by short stature, skeletal deformity and joint hypermobility. Although fracture risk decreases with age, such patients needs regular follow-up with an assessment of bone mineral density (BMD) and, if necessary, correction of therapy to improve the quality of life. Type 1 diabetes mellitus (T1DM) is associated with a decreased BMD, which is mostly attributed to insulin deficiency and hyperglycemia, which also increase the risk of fractures. Achieving and stable maintenance of glycemic targets is often challenging, but it is necessary to exclude hyperglycemia as a factor that further worsens the quality of bone. This paper describes a clinical case of an extremely rare combination of type 1 OI and T1DM, two diseases with a pronounced negative effect on bone tissue. The combination of these pathologies requires special management tactics for such patients to reduce the risk of developing new fractures.

Keywords

osteogenesis imperfect type 1, diabetes mellitus, case report

About the Authors

D. A. Marmalyuk

I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Darya A. Marmalyuk - student; eLibrary SPIN: 6113-6567.

8-2 Trubetskaya street, 119991 Moscow

Competing Interests:

no

G. E. Runova

I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Gyuzel E. Runova - MD, PhD; eLibrary SPIN: 3639-6932.

Moscow

Competing Interests:

no

S. E. Moshenina

I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Sofia E. Moshenina - MD; eLibrary SPIN: 3101-4800.

Moscow

Competing Interests:

no

M. P. Shapka

I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Margarita P. Shapka - MD; eLibrary SPIN: 8871-7115.

Moscow

Competing Interests:

no

V. V. Fadeyev

I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

Valentin V. Fadeyev, MD, Professor; eLibrary SPIN: 6825-8417.

Moscow

Competing Interests:

no

References

1. Tournis S, Dede AD. Osteogenesis imperfecta — A clinical update. Metabolism. 2018;80:27-37. doi: https://doi.org/10.1016/j.metabol.2017.06.001

2. Marini JC, Forlino A, Bächinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. doi: https://doi.org/10.1038/nrdp.2017.52

3. Folkestad L, Hald J, Canudas-Romo V, et al. Mortality and Causes of Death in Patients With Osteogenesis Imperfecta: A Register-Based Nationwide Cohort Study. J Bone Miner Res. 2016;31(12):2159-2166. doi: https://doi.org/10.1002/jbmr.2895

4. Malygina AA, Grebennikova TA, Tiulpakov AN, Belaya ZE. Osteogenesis imperfectaas a cause of death. Osteoporosis and bone diseases. 2018;21(1):23-27. (InRuss.). doi: https://doi.org/10.14341/osteo9733

5. Grebennikova TA, Gavrilova AO, Tiulpakov AN, et al. First description of a type V osteogenesis imperfect clinical case with severe skeletal deformities caused by a mutationp.119C> T in IFITM5 gene in Russia. Osteoporosis and bone diseases. 2019;22(2):32-37. (In Russ.). doi: https://doi.org/10.14341/osteo12103

6. Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A. 2019;179(12):2393-2419. doi: https://doi.org/10.1002/ajmg.a.61366

7. Ishikawa Y, Bächinger HP. A molecular ensemble in the rER for procollagen maturation. Biochim Biophys Acta. 2013;1833(11):2479-2491. doi: https://doi.org/10.1016/j.bbamcr.2013.04.008

8. Gioia R, Panaroni C, Besio R, et al. Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfect pharmacological therapy. Stem Cells. 2012;30(7):1465-1476. doi: https://doi.org/10.1002/stem.1107

9. Janghorbani M, Feskanich D, WillettWC, et al. Prospective study of diabetes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care. 2006;29(7):1573-1578. doi: https://doi.org/10.2337/dc06-0440

10. Yang J, Zhang X, Wang W, et al. Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3KinMG-63 cells. Cell Biochem Funct. 2010;28(4):334-341. doi: https://doi.org/10.1002/cbf.1668

11. Hein GE. Glycationend products in osteoporosis — is there a pathophysiologic importance? Clin Chim Acta. 2006;371(1-2):32-36. doi: https://doi.org/10.1016/j.cca.2006.03.017

12. Farlay D, ArmasLA, Gineyts E, et al. Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus. J Bone Miner Res. 2016;31(1):190-195. doi: https://doi.org/10.1002/jbmr.2607

13. Katayama Y, Akatsu T, Yamamoto M, et al. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res. 1996;11(7):931-937. doi: https://doi.org/10.1002/jbmr.5650110709

14. Fulzele K, DiGirolamo DJ, Liu Z, et al. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem. 2007;282(35):25649-25658. doi: https://doi.org/10.1074/jbc.M700651200

15. Aguiari P, Leo S, Zavan B, et al. High glucose induces adipogenic differentiation of muscle-derived stem cells. Proc Natl Acad Sci USA. 2008;105(4):1226-1231. doi: https://doi.org/10.1073/pnas.0711402105

16. Hemwong N, Phokaew C, Srichomthong C, et al. A patient with combined pituitary hormone deficiency and osteogenesis imperfect associated with mutations in LHX4 and COL1A2. J Adv Res. 2019;21:121-127. doi: https://doi.org/10.1016/j.jare.2019.10.006

17. Wang D, Zhang M, Guan H, et al. Osteogenesis Imperfecta Due to Combined Heterozygous Mutations in Both COL1A1 and COL1A2, Coexisting With Pituitary Stalk Interruption Syndrome. Front Endocrinol. 2019;10:193. doi: https://doi.org/10.3389/fendo.2019.00193

18. Sheremeta MS, Pigarova EA, Kulikova KS. et al. Osteogenesis imperfect in combination with Graves disease. Obesity and metabolism. 2017;14(4):77-82. (InRuss).doi: https://doi.org/10.14341/omet2017477-82

19. Forgács S. Zusammentreffen von Osteogenesis imperfect tarda und familiärem Diabetes melitus [Association of osteogenesis imperfect tarda and familial diabetes mellitus]. Radiologe. 1974;14(3):138-141.

20. Siniachenko VV, Grigorovich LE. Tiazhelaia forma sakharnogo diabeta u bol’noĭ s nesovershennym osteogenezom [Severe form of diabetes mellitusin a female patient with osteogenesis imperfecta]. Klin Med (Mosk). 1982;60(4):98-99.

21. Antoniazzi F, Bertoldo F, Mottes M, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr. 1996;129(3):432-439. doi: https://doi.org/10.1016/s0022-3476(96)70077-x

22. Mc Kiernan FE. Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporos Int. 2005;16(12):1698-1702. doi: https://doi.org/10.1007/s00198-005-1905-5

23. Balkefors V, Mattsson E, Pernow Y, et al. Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta. Physiother Res Int. 2013;18(4):203-211. doi: https://doi.org/10.1002/pri.1546

24. Dwan K, Phillipi CA, Steiner RD, et al. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2014;7:CD005088. doi: https://doi.org/10.1002/14651858.CD005088.pub3

25. Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfect type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Intl. 2012;23(1):285-294. doi: https://doi.org/10.1007/s00198-011-1658-2

26. Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124(2):491-498. doi: https://doi.org/10.1172/JCI71101

27. Gatti D, Rossini M, Viapiana O, et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013;93(5):448-452. doi: https://doi.org/10.1007/s00223-013-9770-2

28. Glorieux FH, Devogelaer JP, Durigova M, et al. Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. J Bone Miner Res. 2017;32(7):1496-1504. doi: https://doi.org/10.1002/jbmr.3143

Supplementary files

	1. Figure 1. Outpatient glucose profile of patient A.
	Subject
	Type	Исследовательские инструменты
	View (268KB)	Indexing metadata ▾

	2. Figure 2. Densitometry of the lumbar spine of patient A.
	Subject
	Type	Исследовательские инструменты
	View (420KB)	Indexing metadata ▾

	3. Figure 3. Lateral radiography of the thoracic and lumbar spine of patient A.
	Subject
	Type	Исследовательские инструменты
	View (185KB)	Indexing metadata ▾

Review

For citations:

Marmalyuk D.A., Runova G.E., Moshenina S.E., Shapka M.P., Fadeyev V.V. Combination of osteogenesis imperfecta and type 1 diabetes mellitus. Diabetes mellitus. 2021;24(5):470-476. (In Russ.) https://doi.org/10.14341/DM12721

Views: 1276

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 2072-0351 (Print)
ISSN 2072-0378 (Online)